Viewing StudyNCT06369285

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:23 PM
Last Modification Date: 2024-10-26 @ 3:27 PM
Study NCT ID: NCT06369285
Status: RECRUITING
Last Update Posted: 2024-04-16
First Post: 2024-04-12
Brief Title: A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive HER2-negative Recurrent or Metastatic Breast Cancer
Sponsor: Puma Biotechnology Inc
Organization: Puma Biotechnology Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Recurrent Breast Cancer
Keywords:
Name View
Metastatic Breast Cancer View
Hormone receptor positive HR View
Human epidermal growth factor receptor 2 negative HER2- View
Recurrent Breast Cancer View